| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 5.84 | 64.0% | 11.0% |
| Total Income | 5.84 | 64.0% | 11.0% |
| Expenditure | 51.68 | 4.5% | 4.3% |
| PBT | -79.22 | 49.3% | 112.4% |
| Net Profit | -81.06 | 51.4% | 114.9% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.22 | 43.5% | 76.8% |
uniQure Announces Q2 2026 Financial Results and Company Update
29 Jul 2026 · 29 Jul, 4:41 pm
Summary
uniQure reported second quarter 2026 revenue of $5.8 million, up from $5.3 million in the prior year, driven by an increase in license revenue. The company also announced a significant $259 million follow-on offering, bolstering its cash position to $810.3 million as of June 30, 2026, and extending its projected cash runway into 2030. Key pipeline developments include regulatory submissions for AMT-130 for Huntington's disease on track for Q3 2026 and expected topline four-year data in September 2026. Preliminary data for AMT-260 showed promising early signals and a favorable safety profile.
Key Highlights
- 1
uniQure reported revenue of $5.8 million for the second quarter of 2026, an increase from $5.3 million in the same period of 2025.
- 2
The company strengthened its financial position with a $259 million follow-on offering, extending its cash runway into 2030.
- 3
U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease are on track for the third quarter of 2026.
- 4
Topline four-year data from the Phase I/II study of AMT-130 is expected in September 2026.
- 5
Preliminary data from the first cohort of the AMT-260 Phase I/IIa trial showed early biological signals of therapeutic activity and a favorable safety profile.
- 6
The net loss for the three months ending June 30, 2026, was $81.1 million, or $1.22 basic and diluted loss per ordinary share.
Management Comments
Matthew Kapusta
This has been a defining quarter – not just for uniQure, but for the Huntington's disease community. Following a productive Type B meeting with the FDA, we remain on track to submit our BLA for AMT-130 in the third quarter — a milestone that reflects years of rigorous science, disciplined execution, and an unwavering commitment to the patients and families living with this devastating disease. With four-year data expected in September and the U.K. regulatory activities progressing as planned, we enter the second half of 2026 with real momentum and a clear line of sight to potentially bringing this therapy to the people who need it. Beyond AMT-130, we continue to execute across our broader pipeline. With a strong balance sheet, we believe we are well-positioned for what will be a transformative period for uniQure and the patients we serve.
Informational and educational content only. Not investment advice.